Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 11/20 | 0.42 |
| ▸ | CYP11B2 | P19099 | 11/20 | 0.42 |
| ▸ | ACACB | O00763 | 1/20 | 0.41 |
| ▸ | NFATC1 | O95644 | 1/20 | 0.39 |
| ▸ | GSK3B | P49841 | 1/20 | 0.39 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | PDE4A | P27815 | 1/20 | 0.32 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.32 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.32 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.32 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.32 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6924573 | 0.90 | CYP11B1 (0.40) | CYP11B1CYP11B2ACACB | |
| SCHEMBL16892169 | 0.84 | ACACB (0.44) | CYP11B1CYP11B2ACACBNFATC1GSK3B | |
| SCHEMBL25946398 | 0.82 | ACACB (0.38) | CYP11B1CYP11B2ACACBNFATC1GSK3B | |
| SCHEMBL31332849 | 0.81 | CYP11B1 (0.44) | CYP11B1CYP11B2 | |
| Hydrochloric Acid SCHEMBL5658937 | 0.81 | ACACB (0.38) | CYP11B1CYP11B2ACACBNFATC1GSK3B | |
| SCHEMBL27762022 | 0.80 | ADORA2B (0.44) | CYP11B1CYP11B2ACACBMEN1KMT2A | |
| SCHEMBL5391398 | 0.79 | CYP11B1 (0.45) | CYP11B1CYP11B2ADORA2AADORA2B | |
| SCHEMBL22623903 | 0.79 | ACACB (0.37) | CYP11B1CYP11B2ACACBNFATC1GSK3B | |
| SCHEMBL21216513 | 0.79 | ACACB (0.44) | CYP11B1CYP11B2ACACBNFATC1GSK3B | |
| SCHEMBL30404186 | 0.78 | ACACB (0.39) | CYP11B1CYP11B2ACACBNFATC1GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8772305-B2 | Substituted pyridinyl-pyrimidines and their use as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-07-08 | — | — | US | disclosed |
| EP-2668177-A1 | SUBSTITUTED PYRIDINYL-PYRIMIDINES AND THEIR USE AS MEDICAMENTS | Boehringer Ingelheim International GmbH (DE) | 2013-12-04 | — | — | EP | disclosed |
| US-20130023502-A1 | SUBSTITUTED PYRIDINYL-PYRIMIDINES AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-01-24 | — | — | US | disclosed |
| US-8268858-B2 | e.g. 5-(3-methoxybenzyloxy)-1H-pyrrolo[2,3-b]pyridine; protein kinases inhibitor; central nervous system disorders; Alzheimer's disease; Parkinson's disease; anticancer, antitumor agents; analgesics; cogestive heart failure; skin disorders; inflammatory bowel disorders; transplant rejection | PLEXXIKON INC. (US) | 2012-09-18 | — | — | US | disclosed |
| US-8268858-B2 | e.g. 5-(3-methoxybenzyloxy)-1H-pyrrolo[2,3-b]pyridine; protein kinases inhibitor; central nervous system disorders; Alzheimer's disease; Parkinson's disease; anticancer, antitumor agents; analgesics; cogestive heart failure; skin disorders; inflammatory bowel disorders; transplant rejection | PLEXXIKON INC. (US) | 2012-09-18 | — | — | US | disclosed |
| WO-2012101013-A1 | SUBSTITUTED PYRIDINYL-PYRIMIDINES AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-08-02 | — | — | WO | disclosed |
| US-20080188514-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC | 2008-08-07 | — | — | US | disclosed |
| US-20080188514-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC | 2008-08-07 | — | — | US | disclosed |
| WO-2008079909-A1 | PYRROLO [2,3-B] PYRIDINES AS KINASE MODULATORS | PLEXXIKON, INC. (US) | 2008-07-03 | — | — | WO | disclosed |
| US-7262185-B2 | Benzazepine derivative, process for producing the same, and use | TAKEDA CHEMICAL INDUSTRIES LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| US-20040235822-A1 | Benzazepine derivative, process for producing the same, and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-11-25 | — | — | US | disclosed |
| EP-1422228-A1 | BENZAZEPINE DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE | Takeda Chemical Industries, Ltd. (JP) | 2004-05-26 | — | — | EP | disclosed |
| EP-1045846-B1 | IMIDAZOLE DERIVATIVES HAVING AN INHIBITORY ACTIVITY FOR FARNESYL TRANSFERASE AND PROCESS FOR PREPARATION THEREOF | LG CHEMICAL LTD (KR) | 2003-05-02 | — | — | EP | disclosed |
| US-6518429-B2 | Anticancer agents, treating restenosis, atherosclerosis and hepatitis virus | LG CHEMICAL, LTD. (KR) | 2003-02-11 | — | — | US | disclosed |
| US-6472526-B1 | SHOWS AN INHIBITORY ACTIVITY AGAINST FARNESYL TRANSFERASE OR PHARMACEUTICALLY ACCEPTABLE SALTS OR ISOMERS THEREOF, IN PHARMACEUTICAL COMPOSITION AND INTERMEDIATES | LG CHEMICAL LTD. (KR) | 2002-10-29 | — | — | US | disclosed |
| US-20020137769-A1 | Imidazole derivatives having an inhibitory activity for farnesyl transferase and process for preparation thereof | LG CHEMICAL LTD. | 2002-09-26 | — | — | US | disclosed |
| US-6268363-B1 | ANTITUMOR | LG CHEMICAL LTD. (KR) | 2001-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130023502-A1 | SUBSTITUTED PYRIDINYL-PYRIMIDINES AND THEIR USE AS MEDICAMENTS | ADORA1, P2RY1, P2RY11 | CYP11B1 397/4885CYP11B2 442/4885ACACB 4526/4885 |
| US-20020137769-A1 | Imidazole derivatives having an inhibitory activity for farnesyl transferase and process for preparation thereof | FNTA, FNTB, FDPS | CYP11B1 74/4885CYP11B2 110/4885ACACB 290/4885 |
| US-20080188514-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, MAP3K13, MAP3K8 | CYP11B1 2149/4885CYP11B2 2264/4885ACACB 1261/4885 |
| US-20040235822-A1 | Benzazepine derivative, process for producing the same, and use | CYP1B1, CYP1A1, CYP2E1 | CYP11B1 51/4885CYP11B2 47/4885ACACB 1852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.